A free, virtual event is to explore the use of psychedelics for alcohol use disorder and binge drinking.
The event, Psychedelics for Alcoholism, held by psychedelic medicine biotech company Clearmind Medicine, will be highlighting new potential treatments for alcohol use disorder and binge drinking.
A panel of scientists, thought leaders, therapists, and more will be sharing their experiences and educating participants on the mounting evidence suggesting the effectiveness of psychedelics, and specifically MEAI, in the regulation of excessive drinking.
Featured speakers include Shannon Smadella, moderator; Adi Zuloff-Shani, Ph.D., chief executive officer at Clearmind; Mark Haden, Advisory Board member, Clearmind; Terri Freeland, construction industry professional; and Dr Jeff Morley, registered psychologist.
Clearmind CEO, Adi Zuloff-Shani, Ph.D., commented: “We’re in the middle of a Psychedelic Renaissance that is revolutionising the way we treat mental disorders.
“We put this event together to increase awareness of the advances being made in the field, and more specifically generate awareness of the work Clearmind is doing with regard to alcohol use and binge drinking.
“Together with our sponsors and partners, we are eager to share our progress and provide access to accurate information to interested communities, including mental health practitioners, researchers, potential patients, investors and the general public.”
Partners of the event include the Canadian Psychedelic Association, World Psychedelics Day, McKenna Academy of Natural Philosophy™, and Insight Global.
Representatives from the Company will also provide an update on Clearmind’s MEAI-based medicines and their potential for the treatment of Alcohol Use Disorder and binge drinking.
The online event will be held 20 October, 2021, starting at 12 PM (EST) and registration is open and free to all.
